The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.
The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.
The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.
CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.